Life Science Tools Market Analysis

Technology (Genomic, Cell Biology, Proteomics, Lab supplies, Other Analytical & Sample Preparation Technology)

Cell biology segment is set to capture over 35% life science tools market share by 2037, also the market held a market value of around USD 64 million. The expansion of this segment can be attributed to the increasing funding for cell biology by the NIH and the importance of cell biology technologies in drug discovery. Additionally, the use of cell-based assays for drug discovery has increased as a result of advancements in liquid handling and flow cytometry.

Additionally, major industry participants have joined forces to conduct cooperative research projects aimed at reprogramming fetal stem cells from blood and umbilical cord tissue into Induced Pluripotent Stem Cells (iPSCs). EdiGene and Haihe Laboratory, for instance, announced a strategic partnership in January 2022 to develop platform technologies and stem cell regenerative medicines. The partnership seeks to investigate new indicators to enhance quality assurance in the generation of stem cells. Over the course of the forecast period, these partnerships are anticipated to boost the life science tools market.

Product Type (Cell Culture Systems & 3D Cell Culture, Liquid Chromatography, Mass Spectrometry, Flow Cytometry, cloning & Genome Engineering, Microscopy & Electron Microscopy, Next Generation Sequencing, PCR & qPCR, Nucleic Acid Preparation, Nucleic Acid Microarray, Sanger Sequencing, Transfection devices & Gene Delivery Technologies, NMR)

By 2037, cell culture & 3D cell culture segment is anticipated to dominate over 20% life science tools market share. Exploring the possibilities of cell biology & automated cell culture through research has produced significant breakthroughs that have increased profitability. A thorough understanding of cell biology has emerged as a valuable tool for laboratory workflows, creating new opportunities for market growth. It is anticipated that the segment will continue to grow as a result of scientists in the life science field being willing to adopt new and advanced instruments.

A number of important manufacturers have been inspired to diversify their instrument ranges by this industry trend. For example, a number of companies, including Cytiva, BioTek devices, Horizon Discovery, and Seahorse Bioscience, are working to introduce devices for imaging, cell biology, and analysis.

End-use (Government & Academic, Biopharmaceutical Company, Healthcare, Industrial Applications) 

Healthcare segment share is anticipated to account for 32% life science tools market share by 2037. The expansion will continue to be fueled by an increase in the use of proteomic and genomic processes in hospitals for the diagnosis and treatment of various diseases.

Additionally, the life science tools market is anticipated to be driven by hospitals' increasing use of NGS and tissue diagnostic services. Presently, several clinics and hospitals offer sequencing services to their patients and are figuring out how to employ cutting-edge instruments and technology in day-to-day medical practice. One such hospital that offers sequencing services to patients with uncommon or undetected genetic conditions is Stanford Medicine.

One of the first hospital systems in the United States to provide public genetic sequencing, analysis, and interpretation services is Partners HealthCare. It is anticipated that genomic sequencing in a hospital or clinical context will reduce healthcare expenses and enhance patient care. As a result, the healthcare sector is expected to grow more rapidly over the coming years.

Our in-depth analysis of the market includes the following segments: